Discovering human cell‐compatible gene therapy virus variants via optimized screening in mouse models

Abstract

AbstractIn gene therapy, intravenous injection of viral vectors reigns as the primary administration route. These vectors include adeno‐associated viruses, adenoviruses, herpes viruses, rhabdoviruses and others. However, these naturally occurring viruses lack inherent tissue or organ tropism for tailored disease treatment. To address this, we devised an optimized process involving directed viral capsid evolution, organ‐specific humanized mouse models and in vitro‐in vivo virus screening. Our approach allows for the rapid generation specifically modified adeno‐associated virus variants, surpassing the time required for natural evolution, which spans millions of years. Notably, these variants exhibit robust targeting of the liver, favouring chimeric human liver cells over murine hepatocytes. Furthermore, certain variants achieve augmented targeting with reduced off‐target organ infection, thereby mitigating dosage requirements and enhancing safety in gene therapy.